Y-mAbs Therapeutics (YMAB) Tops Q4 EPS by 47c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Y-mAbs Therapeutics (YMAB) Tops Q4 EPS by 47c

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

March 30, 2023 4:01 PM EDT

Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidanceFirst ever SADA Phase I trial opened Cash and cash equivalents of $105.8 million as of December 31, 2022, anticipated runway into the first quarter 2026The Company will host a conference call on Friday, March 31, 2023, at 9 a.m. EST

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq:... More